Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAEleanor DanielsonCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAFrancisco Antônio Helfenstein FonsecaUniversidade Federal de Sao Paulo, Sao Paulo, BrazilJacques GenestMcGill University Health Center, Montreal, Quebec, CanadaAntonio M. GottoWeill Cornell Medical College of Cornell University, New York, NY, USAJohn J.P. KasteleinDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, NetherlandsWolfgang KöenigUniversity of Ulm Medical Center, Ulm, GermanyPeter LibbyDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAAlberto LorenzattiHospital Cordoba, Cordoba, ArgentinaJean MacFadyenCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USABørge G. NordestgaardHerlev Hospital, Copenhagen University Hospital, Herlev, DenmarkJames ShepherdUniversity of Glasgow, Glasgow, UKJames T. WillersonSt Luke's Episcopal Hospital/Texas Heart Institute, Houston, TX, USARobert J. GlynnCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2009en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba